Anti-IgE vaccines
AssigneesPfizer Inc., Pfizer Products Inc.
InventorsMohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
Claims8
An isolated antigenic peptide consisting of SEQ ID NO:
- 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.
An isolated antigenic fusion protein comprising a CH3 domain of an IgE molecule consisting of SEQ ID NO:
- 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal;
- and a heterologous carrier protein fused to said CH3 domain.
A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic peptides of a CH3 domain of an IgE molecule wherein said one or more antigenic peptide consists of SEQ ID NO:
- 4.
A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigertic peptides of a CH3 domain of an IgE molecule wherein one or more of said antigenic peptide consists of SEQ ID NO:
- 4;
- and a heterologous carrier protein fused to one or more of said antigenic peptide.
Dependencies are inferred from the claim text.